中山醫學大學機構典藏 CSMUIR:Item 310902500/23692
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17905/22920 (78%)
Visitors : 7510555      Online Users : 497
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    CSMUIR > researcher portal > Artical >  Item 310902500/23692
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23692


    Title: Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
    Authors: Park, K;Janne, PA;Kim, DW;Han, JY;Wu, MF;Lee, JS;Kang, JH;Lee, DH;Cho, BC;Yu, CJ;Pang, YK;Felip, E;Kim, H;Baek, E;Noh, YS
    Keywords: epidermal growth factor receptor;non-small cell lung cancer;olmutinib;T790M;tyrosine kinase inhibitor
    Date: 2021
    Issue Date: 2022-08-05T09:41:21Z (UTC)
    Publisher: WILEY
    ISSN: 0008-543X
    Abstract: BACKGROUND: In this open-label, international phase 2 study, the authors assessed the efficacy and safety of olmutinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had a confirmed T790M mutation and disease progression on previous epidermal growth factor receptor-tyrosine kinase inhibitor therapy. METHODS: Patients aged >= 20 years received once-daily oral olmutinib 800 mg continuously in 21-day cycles. The primary endpoint was the objective response rate (patients who had a confirmed best overall response of a complete or partial response), assessed by central review. Secondary endpoints included the disease control rate, the duration of objective response, progression-free survival, and overall survival. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03). RESULTS: Overall, 162 patients (median age, 63 years; women, >60%) were enrolled from 68 sites in 9 countries. At the time of database cutoff, 23.5% of enrolled patients remained on treatment. The median treatment duration was 6.5 months (range, 0.03-21.68 months). Overall, 46.3% of patients (95% CI, 38.4%-54.3%) had a confirmed objective response (all partial responses). The best overall response (the objective response rate regardless of confirmation) was 51.9% (84 patients; 95% CI, 43.9%-59.8%). The confirmed disease control rate for all patients was 86.4% ( 95% CI, 80.2%-91.3%). The median duration of objective response was 12.7 months (95% CI, 8.3-15.4 months). Estimated median progression-free survival was 9.4 months (95% CI, 6.9-12.3 months), and estimated median overall survival was 19.7 months (95% CI, 15.1 months to not reached). All patients experienced treatment-emergent adverse events, and 71.6% of patients had grade >= 3 treatment-emergent adverse events. CONCLUSIONS: Olmutinib has meaningful clinical activity and a manageable safety profile in patients with T790M-positive non-small cell lung cancer who received previous epidermal growth factor receptor-tyrosine kinase inhibitor therapy. Cancer 2020;0:1-10. (c) 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
    URI: http://dx.doi.org/10.1002/cncr.33385
    https://www.webofscience.com/wos/woscc/full-record/WOS:000606964500001
    https://ir.csmu.edu.tw:8080/handle/310902500/23692
    Relation: CANCER ,2021,v127,issue 9, P1407-1416
    Appears in Collections:[researcher portal] Artical

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML305View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback